Abzorb

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abzorb

Quick Facts

Property Description
Active ingredient Clotrimazole
Form Cream, Dusting Powder, Solution, Lotion
Pharmacological class Azole Antifungal (Imidazole Derivative)
Common use Management of Fungal Skin Infections
Origin Synthetic compound

What Type of Medicine is Abzorb and Its Primary Composition?

The preparation known by the trade name Abzorb is a specialized topical antifungal medicine, fundamentally defined by its active ingredient, clotrimazole. This substance belongs to the azole antifungal family, specifically classified within the imidazole class. This classification immediately identifies the medication as an agent designed for the localized management of surface fungal infections.

Clotrimazole is a synthetic derivative compound, not naturally occurring, which determines the identity and core function of the preparation. Abzorb is primarily a single active ingredient product, although combination formulations that incorporate agents like corticosteroids exist as a marketplace variant. The high-level composition utilizes the active compound alongside an inert base or vehicle appropriate for the form; for instance, the cream base facilitates topical delivery, while the dusting powder incorporates carriers like talc and starch to manage moisture in the application area.

Understanding the Forms and General Therapeutic Purpose

Abzorb is made available in several key pharmaceutical preparations for external use only, which typically include a cream, a dusting powder, a solution, and a lotion, suitable for various sites requiring topical administration. This versatility in form is a differentiating factor, allowing patients options for application to different skin textures and locations.

The general therapeutic use of this antifungal medication is to control the localized growth of pathological fungi on the skin. The product's mechanism achieves its purpose by exploiting the structural differences between fungal and human cells, a physiological action that is supported by professional monographs and clinical recognition. This action stems from its ability to interfere with the fungal organism's structure, ensuring the product's function is strictly limited to eliminating or arresting the pathogenic fungal cell population responsible for fungal skin infections and dermatomycoses.

What side effects are possible with Abzorb?

Safety Profile for Bioresorbable Devices (Abzorb, Absorb, BioZorb)

The safety profile for products marketed under names such as Absorb (Bioresorbable Vascular Scaffold) and BioZorb (Implantable Marker) is largely defined by the risks inherent to implanted, bioresorbable devices, as documented by regulatory bodies.

Serious and Clinically Significant Adverse Reactions

For the bioresorbable coronary scaffold (Absorb), serious risks include major adverse cardiac events such as scaffold thrombosis (blood clot formation on the device) and myocardial infarction (heart attack). Clinical data indicated a higher rate of these events compared to standard metallic stents, particularly in the first few years post-implantation.

For the implantable marker (BioZorb), serious adverse events reported following placement in soft tissue, such as breast tissue, include:

  • Local Adverse Reactions: Infection, pain, rash, seroma (fluid buildup).
  • Device-Related Issues: Device migration (moving from the original position) and device erosion (breaking through the skin).

Regulatory Safety Limitations and Classifications

Classification/Limitation Details (Based on Regulatory Documents)
Cardiovascular Restriction The Absorb scaffold is contraindicated for use in coronary vessels determined to be less than 2.5 mm in diameter, which is associated with an increased risk of adverse events.
Marker Recall Status The U.S. Food and Drug Administration (FDA) has identified a Class I recall for the BioZorb Marker, the most serious type of recall, directing against the implantation of unused devices due to the risk of serious adverse health consequences.
Safety Monitoring Patients with an implanted coronary scaffold are required to adhere to an extended regimen of dual antiplatelet therapy to mitigate the risk of thrombosis.

The overall official safety information for these products emphasizes a distinct set of risks tied to the bioresorbable material and mechanical limitations compared to permanent implant alternatives. Regulatory actions focus on strict limitations for use and warnings against the continued implantation of the marker device.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The regulatory profile for topical Clotrimazole (Abzorb) establishes that acute intoxication is unlikely following its intended external use, even if a large area of the skin is covered. The minimal systemic absorption from dermal application means overdosage is not expected to lead to a life-threatening situation.

The primary scenario addressed by official labeling is inadvertent oral ingestion. Following this event, you must seek urgent medical evaluation. While intoxication remains unlikely, symptoms that may become apparent include dizziness, nausea, or vomiting.

Official guidance mandates that treatment is limited to symptomatic and supportive measures because no specific antidote is known. Intervention such as gastric lavage is rarely required and is only considered if a life-threatening amount of the substance was ingested within the preceding hour or if clinical symptoms develop. The official overdose statements do not specify differential risks for particular populations, such as pediatric or elderly patients, concerning single-ingredient topical overdose. The entire official profile emphasizes the unlikely risk of severe systemic effects from this topical product.

Therapeutic Uses of Abzorb

Main Uses of Abzorb

Abzorb is a topical antifungal medication used primarily to manage and resolve skin infections caused by various types of fungi. It is commonly employed to address common fungal conditions that thrive in warm, moist areas of the body.

Primary Conditions Treated

  • Athlete's Foot (Tinea Pedis): Manages fungal infections affecting the feet, particularly between the toes, characterized by itching, scaling, and redness.
  • Jock Itch (Tinea Cruris): Used for infections in the groin and inner thigh area, which often present as an itchy, red, ring-shaped rash.
  • Ringworm (Tinea Corporis): Addresses fungal infections on the torso, arms, or legs that typically appear as circular, itchy patches with clearer centers.
  • Fungal Sweat Rash: Helps manage skin irritation and infection occurring in skin folds, such as under the breasts, in the armpits, or in other areas prone to perspiration and friction.

Key Benefits

Eradication of Fungal Pathogens

The active component in Abzorb works by disrupting the integrity of the fungal cell membrane. By inhibiting the synthesis of essential components, the medication stops the growth of the fungus and eventually eliminates the infection at its source.

Relief of Physical Symptoms

One of the primary benefits of the treatment is the systematic reduction of uncomfortable symptoms associated with fungal overgrowth. This includes the alleviation of:

  • Persistent itching and burning sensations.
  • Skin inflammation and redness.
  • Cracking, scaling, and peeling of the skin.

Prevention of Secondary Complications

By controlling the initial fungal infection, the medication helps maintain skin barrier integrity. This reduces the likelihood of secondary bacterial infections that can occur when the skin becomes broken or severely irritated due to scratching and inflammation.

Regulatory References

  1. NIH MedlinePlus overview of Clotrimazole Topical

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Abzorb (Topical Clotrimazole)

The population eligibility for Abzorb, a topical antifungal, is defined by regulatory documents based on contraindications, age, and application site, reflecting its minimal systemic absorption.

Contraindications and Non-Eligible Populations

Classification Eligibility Statement
Absolute Contraindication Individuals with known hypersensitivity (allergy) to clotrimazole or to any excipient component in the formulation must not use the medicine.
Anatomical Prohibition The preparation is not approved for ophthalmic use (use in the eyes).
Efficacy Limitation Use is not effective for fungal infections of the nails (onychomycosis) or the scalp.

Age- and Physiological-Based Eligibility

Age-Related Use is established for adults, adolescents, and children mathbf2 years of age and older. Use in children younger than mathbf2 years is restricted and generally requires the direction of a healthcare provider.

Pregnancy and Lactation status is generally permitted during the second and third trimesters, due to minimal systemic absorption. Use during the first trimester is restricted and should be authorized by a physician. The drug is permitted while breastfeeding, but application to the breast area should be avoided.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Abzorb (clotrimazole topical) has a highly constrained interaction profile due to its minimal systemic absorption when applied to intact skin. This lack of significant drug concentration in the bloodstream means that most systemic drug-drug interactions documented for other azole antifungals are not considered clinically relevant for the cream, powder, or solution formulations. Regulatory labeling confirms that the theoretical potential for metabolic interference, such as CYP3A4 inhibition, does not result in clinically significant interactions with co-administered medicines.

Documented Interaction Patterns

Interacting Substance Interaction Type Regulatory Context
Latex Contraceptives Local/Physical Damage Topical application, especially to the genital area, may damage latex materials (e.g., condoms, diaphragms).
Systemic Tacrolimus/Sirolimus Increased Exposure Risk Potential for increased plasma concentrations of these immunosuppressants is documented, but primarily for formulations with higher absorption (e.g., vaginal), which necessitates monitoring.

Restrictions and Requirements

For the formulations with measurable systemic absorption, such as the vaginal product, a mandatory requirement for alternative contraceptive precautions is noted for at least five days following use, due to the risk of latex damage. There are no documented interactions between topical clotrimazole and food, alcohol, or common herbal supplements in the official regulatory prescribing information.

Mechanism of Action

The mechanism of action of clotrimazole is defined by a precise physiological action that disrupts the unique structural chemistry of the fungal cell. The active ingredient functions as an inhibitor of the enzyme lanosterol 14-alpha demethylase left(P45014DM ight). This fungal-specific enzyme is essential for the ergosterol biosynthesis pathway. By blocking this step, the drug prevents the fungus from synthesizing ergosterol, a principal sterol component required for its cell membrane structure.

The inhibition of sterol production leads to a critical mechanistic cascade: the fungal membrane becomes severely depleted of ergosterol while accumulating toxic, non-functional methylated sterols. This dual disruption compromises the membrane’s stability and integrity, causing it to lose control over permeability. This structural failure results in the uncontrolled leakage of essential cellular contents (such as ions and phosphorus compounds) and leads to the functional collapse and cytotoxicity of the fungal organism, inducing cellular destruction based on concentration.

Dosage and Administration Information

Official Administration Guidelines for Abzorb (Clotrimazole Topical)

The usage of Abzorb, which contains the active ingredient clotrimazole, is defined by its topical route of administration. The medication is available in dosage forms such as a 1% cream and a 1% solution for dermal application.

Dosing Schedule and Application

Parameter Official Instruction
Route of Administration For external use only (dermal application). Not for ophthalmic or oral use.
Dosing Frequency Apply a sufficient quantity to the affected area twice daily (morning and evening).
Preparation The infected skin area must be washed and thoroughly dried before each application.
Duration (Tinea Cruris) Use daily for the full course of 2 weeks.
Duration (Tinea Pedis/Corporis) Use daily for the full course of 4 weeks; the diagnosis should be reviewed if no improvement is observed after this period.

The protocol involves gently massaging the preparation into the affected skin and the surrounding boundaries. For children 2 years of age and older, the same twice-daily frequency is applicable, though supervision is recommended. If a dose is missed, it is typically applied as soon as it is remembered, or skipped if it is nearly time for the next scheduled dose. The entire course of treatment is intended to be completed, even after initial symptom resolution.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Abzorb

Evidence for Use in Primary Approved Condition

Research on Abzorb’s primary use was evaluated in multiple Randomized, Controlled Trials (RCTs). These trials were designed to examine how Abzorb was observed in populations of adults presenting with the primary condition, including those with both moderate and severe manifestations. Researchers primarily monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, using specialized scales and patient-reported outcomes describing perceived discomfort to assess experiences over defined time intervals.

The studies monitored Abzorb across defined time intervals, including short-term periods and periods lasting up to one year. Studies reported how symptoms evolved in the observed populations. Reported changes measured during the study period were similar across the main, short-term RCTs, but long-term secondary outcomes described variability. Research also examined changes in certain disease biomarkers during the study period. Additionally, the trials documented the rates at which participants left the studies and the data show patterns related to overall changes measured during the study.

Long-Term Studies and Follow-up

Research available so far covers outcomes up to three years in the longest extension studies; however, certainty remains low regarding outcomes beyond this period. The collection of continuous data for many outcomes decreases after the initial studies, and limited information for long-term outcomes means that the long-term pattern of change and the evolution of the condition after three years are areas where certainty remains low.

Evidence in Special Populations

Research has been conducted in various groups, including studies that examined pediatric populations (children and adolescents). Researchers also monitored patterns observed in subgroups of older adults. For specific subgroups, such as the very elderly or those with complex organ function issues, data for certain groups remain insufficient. Research exploring how symptoms evolved in these limited populations contributes to the broader evidence landscape.

What is Still Uncertain About Abzorb Research

The primary limitation is that long-term effects are not fully established. Data for certain groups remain insufficient, especially for highly specific populations. The relationship between certain changes in biomarkers monitored in the studies and long-term patient-reported outcomes describing perceived discomfort is an area where data are still emerging, and certainty remains low.

Frequently Asked Questions (FAQ)

Common questions about Abzorb (FAQ)

Q: What is the full list of conditions Abzorb is used for?

A: Official product information describes Abzorb (Clotrimazole Topical) as an agent used for the management of dermal fungal infections. This includes conditions such as tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). It is also indicated for candidiasis infections caused by Candida albicans.

Q: Is Abzorb a new type of medicine?

A: Abzorb contains the active ingredient clotrimazole, which is a synthetic imidazole antifungal compound. This type of drug has been used in medicine for many years, making it a well-established and long-standing treatment option according to regulatory classifications.

Q: What are the most common side effects that patients experience with Abzorb?

A: Official safety reports indicate that the most common adverse reactions occur locally at the application site. These side effects can include signs of skin irritation, such as mild burning, stinging, itching, or redness (erythema). Some patients may also notice peeling or blistering of the skin.

Q: Do the side effects of Abzorb typically go away over time?

A: Mild local symptoms like burning or irritation may occur when first starting the product. However, official information notes that increased irritation or signs of allergic sensitization could also occur. Any persistent or severe symptoms warrant consultation with a healthcare professional.

Q: Are there any serious but rare side effects to be aware of when taking Abzorb?

A: Serious adverse reactions are described as rare for the topical formulation. Official warnings state that signs of allergic sensitization, such as rash or hives, or severe local reactions like significant blistering, swelling, or oozing, warrant immediate consultation with a healthcare professional.

Q: What signs or symptoms should prompt a person to call a doctor while on Abzorb?

A: Regulatory guidance suggests consulting a healthcare provider if there is no improvement in symptoms after a full treatment course. Additionally, a doctor should be consulted if the application area shows increasing irritation, such as severe redness, itching, burning, or swelling.

Q: Does taking Abzorb cause weight changes (gain or loss)?

A: Weight change (gain or loss) is not listed as a reported side effect for the topical formulation in official documents. This is consistent with the drug's minimal systemic absorption, meaning very little of the active ingredient enters the bloodstream.

Q: Can Abzorb make you feel sleepy or tired?

A: Central Nervous System (CNS) effects like fatigue or drowsiness are not reported as side effects for the topical formulation. This is expected given its minimal systemic absorption, which limits the drug’s exposure to the central nervous system.

Q: Does Abzorb interact with common over-the-counter pain relievers like Tylenol (acetaminophen) or Advil (ibuprofen)?

A: Regulatory documents state that due to the minimal absorption of the topical formulation through the skin, there are no clinically significant systemic drug interactions expected. This lack of interaction includes common over-the-counter pain relievers such as acetaminophen or ibuprofen.

Q: What is the risk of an interaction if I am taking Abzorb along with a common blood pressure medicine?

A: Because topical clotrimazole has negligible systemic absorption, it is highly unlikely to cause clinically significant interactions with medications that work systemically, such as common blood pressure medicines. The drug primarily acts locally on the skin’s surface.

Q: How long does it usually take for Abzorb to start working?

A: Official clinical data indicate that patients usually start to see clinical improvement, including relief from symptoms like itching, within the first week of treatment.

Q: How soon will I notice the full benefit or effect of Abzorb?

A: The full benefit is generally observed upon completion of the full treatment course required for the specific infection being managed, as defined in the product labeling. Treatment must be completed even if symptoms appear to resolve earlier.

Q: Do I need to take Abzorb for a long time, or is it a short-term treatment?

A: Official information defines Abzorb as a short-term treatment, with prescribed, defined, short treatment courses. This differs from medications intended for chronic or long-term management.

Q: What happens if a person stops taking Abzorb suddenly?

A: Official instructions advise patients to use the medicine for the full prescribed treatment time, even if the condition appears to be healing. Stopping the use of the product too early may risk the fungal infection recurring or not clearing completely.

Q: Are there any known safety concerns for people with kidney issues who want to use Abzorb?

A: Due to the minimal amount of the topical drug that enters the bloodstream (negligible systemic absorption), specific guidelines for dosage adjustments related to kidney function are generally not required for this topical product.

Q: Can people with liver disease or liver problems safely use Abzorb?

A: The topical formulation carries a low risk of affecting the liver because it has minimal systemic absorption. While liver function is a consideration for oral antifungal drugs, the minimal exposure with the topical form lessens the risk of clinically relevant liver effects.

Q: Is Abzorb safe to use for teenagers or children?

A: The product label indicates use for children aged 2 years and older. The topical cream and solution formulations are approved for this age group.

Q: Can Abzorb be used by people with diabetes or high blood sugar?

A: While the topical skin product does not have specific warnings for diabetes, regulatory labeling for related forms sometimes notes that frequent or recurrent infections could be a signal of an underlying condition. Recurrent infections should be addressed by a healthcare professional.

Q: Is Abzorb a controlled substance?

A: Clotrimazole topical, the active ingredient in Abzorb, is not scheduled by government regulatory bodies and is not considered a controlled substance.

Q: Is there a generic version of Abzorb available yet?

A: Yes, the active ingredient is Clotrimazole, which is widely available as a generic product. This generic form is often available over-the-counter (nonprescription) in many countries.

Q: Why is Abzorb considered a prescription-only medicine?

A: Products containing Clotrimazole are available in both prescription (Rx) and over-the-counter (OTC) forms. The prescription status often depends on the strength, specific format, and the indication (the condition it is approved to treat).

Q: Are there different strengths or forms of Abzorb?

A: Yes, the active ingredient is available in different forms, including a cream, solution, powder, and vaginal preparations. It is most commonly supplied in a 1% strength for skin infections, but other forms may have different concentrations.

Q: Where can I find the official Consumer Medicine Information (CMI) leaflet for Abzorb?

A: Official product information for Abzorb is available through resources such as the Patient Counseling Information section of the regulatory label (like the FDA DailyMed label). These documents contain the full official safety and usage details.

Q: What were the main findings of the clinical trials for Abzorb?

A: Clinical trials for Clotrimazole topical demonstrated the drug's efficacy (how well it works) against the specific fungal organisms it is approved to treat. The findings include documented clinical and microbiological cure rates for the approved indications.

Q: What is the reported effectiveness rate for Abzorb in official studies?

A: Official regulatory information cites the specific cure rates and improvement percentages achieved in clinical trials for the approved conditions. These rates are used by authorities to support the product's effectiveness claims.

Q: Did the clinical trials for Abzorb include a diverse group of patients?

A: Research evidence submitted to authorities confirms that studies have been conducted to monitor patterns observed in specific subgroups. This includes pediatric populations (children and adolescents) and older adults.

Q: Is the research evidence for Abzorb considered strong by medical authorities?

A: The research evidence supporting the use of Abzorb is considered strong by regulatory authorities for its approved indications. This approval is based on multiple Randomized Controlled Trials (RCTs) that demonstrated the drug's safety and effectiveness.

Q: Is there an official statement about Abzorb's safety during pregnancy?

A: Official safety data generally consider Clotrimazole topical acceptable for use during pregnancy. However, as with all medicines, consultation with a healthcare professional before use is generally warranted.

Q: What does official guidance say about using Abzorb while breastfeeding?

A: Due to minimal systemic absorption, the product is generally considered safe to use while breastfeeding. It is highly unlikely that clinically significant amounts of the drug would pass into breast milk.

Q: Can Abzorb impact the results of common blood tests?

A: Because very little of the topical drug enters the bloodstream (minimal systemic absorption), Abzorb is not expected to affect the results of common blood tests.

Q: What happens if I take Abzorb and it does not seem to be helping my condition?

A: Official counseling advises that patients notify their physician if they do not see any improvement in their condition after 4 weeks of treatment. This lack of response may indicate that the original diagnosis needs to be re-evaluated by a healthcare professional.

Q: Is a person considered eligible to take Abzorb if they have a history of heart problems?

A: Since the amount of drug absorbed systemically is minimal, heart problems are not listed as a contraindication or special warning for the topical product in official labels. The risk of systemic effects that could impact the heart is considered very low.

Q: Is there a potential for a temporary worsening of symptoms when first starting Abzorb?

A: Official information mentions that a mild increase in burning, itching, or irritation may occur when a patient first starts using the product. This is sometimes cited as a mild, expected adverse reaction during the initial phase of treatment.

Q: Does Abzorb have an effect on mental alertness or ability to drive?

A: Central Nervous System (CNS) effects that could reduce mental alertness, such as drowsiness, are not listed as known adverse effects for the topical product. This is consistent with its minimal systemic absorption.

Q: Can Abzorb cause skin sensitivity to sunlight?

A: While local skin reactions are common, official drug precautions do not list photosensitivity (increased skin sensitivity to sunlight) as a specific adverse reaction or warning for the topical formulation.

Q: Is it necessary to have routine follow-up appointments or lab work while on Abzorb?

A: Routine lab work is not generally required for the topical product because of its minimal systemic absorption. Follow-up is typically only needed if the symptoms fail to improve after the full course of treatment.

Q: Is Abzorb known to affect fertility in men or women?

A: Based on official regulatory safety data, there is no evidence indicating that Clotrimazole topical affects fertility in either men or women.

Q: Is there a risk of developing a dependence on Abzorb?

A: Official information and professional monographs indicate that there is no known risk of physical or psychological dependence associated with the use of Clotrimazole topical.

Q: Is Abzorb known to cause headaches?

A: Headaches are not listed as a reported adverse effect for the topical formulation. This is expected given the drug’s minimal entry into the systemic circulation.

Q: Is it common for doctors to start with a lower dose of Abzorb?

A: The standard regimen described in regulatory documents is a standard prescribed regimen for the entire duration of the course. Official information does not mention an initial dose titration or lower starting dose for the topical product.

How should Abzorb be stored and disposed of?

Official Storage and Disposal Instructions

Abzorb (clotrimazole topical) must be stored and handled according to the instructions defined in the official regulatory product labeling to maintain its stability and effectiveness.

Storage Requirement Official Condition
Temperature Store below 30 C (Controlled Room Temperature). Do not freeze.
Environment Protect from light and moisture. Store in a dry place.
Packaging Keep the medicine in its original container, tightly closed.
Safety Keep out of the sight and reach of children.

Disposal of unused or expired Abzorb must follow local requirements. Regulatory bodies advise against disposing of the medicine by flushing it down the toilet or throwing it in household trash unless first mixed with an undesirable substance, which should then be placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Abzorb found in:

A-Z Index: